This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

GSK Responds to Hurricane Sandy Relief Needs

Issued: Friday 09 November 2012, Philadelphia

GlaxoSmithKline (GSK) has donated $250,000 to the American National Red Cross to help victims of Hurricane Sandy in the United States. The company also is contributing $80,000 through the British Red Cross for relief efforts in the wider Caribbean region – specifically Haiti, Cuba, Jamaica and the Dominican Republic – where Sandy initially made landfall.  GSK is also matching dollar-for-dollar all employee contributions to the Red Cross and other relief organizations in the US. 

The company is currently working through the process for an additional donation to support relief efforts in New Jersey.

“Our hearts go out to those who have experienced loss due to the storm,” said Deirdre Connelly, President, North America Pharmaceuticals. “We hope our support will help relief workers respond to their most pressing needs.”

GSK is working to support directly its US employees who have been seriously affected by the storm. 

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).

GlaxoSmithKline Inquiries:   
UK Media enquiries: David Daley +44 (0) 20 8047 5502 London
US Media Inquiries: Mary Anne Rhyne  +1 919 483 0492  North Carolina

 

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.